tiprankstipranks
Trending News
More News >
Seer (SEER)
NASDAQ:SEER
US Market

Seer (SEER) AI Stock Analysis

Compare
132 Followers

Top Page

SE

Seer

(NASDAQ:SEER)

Rating:55Neutral
Price Target:
$2.00
▼(-5.66%Downside)
Seer's overall stock score reflects a company with strong strategic initiatives and revenue growth potential, as highlighted in the earnings call. However, significant challenges in profitability, cash flow management, and valuation weigh heavily on the score. The technical analysis suggests uncertain momentum, further contributing to the moderate overall score.
Positive Factors
Operational Performance
The number of instruments shipped in the quarter matched the total for the entire previous year, demonstrating strong demand and operational performance.
Revenue Growth
Product revenue grew 73%, exceeding expectations, despite pressure on budgets and extended sales cycles.
Service Expansion
Service revenue increased significantly, driven by STAC-related revenue, highlighting the importance of this service in expanding platform access.
Negative Factors
Government Funding Risk
Uncertain NIH funding is a risk, with significant sales to direct US government labs and US universities.
Product Revenue Decline
Seer, Inc. saw a decline in product revenue driven by a decrease in instrument sales due to pressure on capital expenditure budgets and longer sales cycles.
Revenue Guidance
Revenue guidance remains cautious due to uncertainty around government funding and US tariff policies affecting market visibility.

Seer (SEER) vs. SPDR S&P 500 ETF (SPY)

Seer Business Overview & Revenue Model

Company DescriptionSeer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
How the Company Makes MoneySeer generates revenue through the sale of its Proteograph Product Suite and related consumables, which are essential for conducting proteomic analyses. The company's revenue model primarily includes the direct sale of these products to research institutions, pharmaceutical companies, and academic labs. Additionally, Seer may engage in strategic partnerships and collaborations with other biotech firms and research organizations to expand its market reach and enhance its technological offerings. Through these collaborations, Seer can also generate revenue through licensing agreements and joint development projects.

Seer Earnings Call Summary

Earnings Call Date:May 13, 2025
(Q1-2025)
|
% Change Since: 10.42%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted robust revenue growth and significant achievements, including securing a major contract for a large-scale study and expanding partnerships. However, these positives were tempered by ongoing macroeconomic challenges, pressure on budgets, and uncertainty in government funding. Despite these concerns, Seer remains optimistic about its growth prospects.
Q1-2025 Updates
Positive Updates
Strong Start to 2025 with Revenue Growth
Seer delivered $4.2 million in revenue for the first quarter of 2025, marking a 37% increase compared to $3.1 million in the first quarter of 2024.
Significant Contract Secured for Large-Scale Study
Discovery Life Sciences, in collaboration with Seer, secured a contract for a 10,000-sample study using the Proteograph product suite, marking a milestone for the proteomics market.
High Customer Engagement with STAC
Half of the instrument shipments in Q1 were from customers who had previously accessed STAC, representing the highest number of STAC-to-instrument conversions in a single quarter.
Partnership with Thermo Fisher Scientific
Expanded partnership to co-market and sell the Proteograph product suite alongside Orbitrap Astral mass spectrometer, enhancing commercial reach.
Reduced Operating Expenses
Total operating expenses decreased by 14% to $22.8 million in Q1 2025 compared to $26.6 million in Q1 2024, driven by decreases in stock-based compensation and laboratory expenses.
Negative Updates
Macroeconomic Volatility and Tariff Impact
Ongoing macroeconomic challenges, including tariffs and government funding issues, are expected to persist, affecting visibility for the year.
Pressure on CapEx Budgets and Elongated Sales Cycles
Continued pressure on CapEx budgets and elongated sales cycles for purchasing new instruments were observed, despite positive Q1 results.
Reduced NIH and Government Funding
NIH and government funding environment remains uncertain, affecting the academic and government segments, which represent 30% of overall revenue.
Net Loss for the Quarter
The company reported a net loss of $19.9 million for Q1 2025, compared to $20.7 million in Q1 2024.
Company Guidance
During Seer's first quarter 2025 earnings call, the company reiterated its full-year revenue guidance of $17 to $18 million, anticipating 24% year-over-year growth at the midpoint. The company reported a strong start to the year with $4.2 million in revenue for the first quarter, a 37% increase compared to the previous year, driven by high demand for the Proteograph product suite. Gross profit reached $2.1 million, with a gross margin of 49%, up from 44% in the same quarter of 2024. Operating expenses decreased by 14% to $22.8 million. Despite macroeconomic pressures, including tariff implications and funding uncertainties, Seer maintains a robust balance sheet with approximately $285 million in cash, cash equivalents, and investments, allowing them to continue strategic investments in R&D and share repurchase programs. The company expects free cash flow loss to be between $40 million and $45 million for the year, while managing to repurchase 352,000 Class A shares in the first quarter.

Seer Financial Statement Overview

Summary
Seer demonstrates strengths in its equity position with a low debt-to-equity ratio and solid capital structure. However, the company faces significant challenges in profitability, with a negative net profit margin and inconsistent revenue growth, indicating potential volatility.
Income Statement
55
Neutral
Seer shows modest revenue growth in the TTM, with a Gross Profit Margin of 40.3%. However, the company faces significant challenges with profitability, as evidenced by a negative Net Profit Margin of -56.6% and negative EBIT and EBITDA margins. Revenue growth has been inconsistent, indicating potential volatility and challenges in sustaining revenue growth.
Balance Sheet
65
Positive
The company has a strong equity position with a low Debt-to-Equity Ratio of 0.08, indicating low leverage. The Equity Ratio stands at 89.6%, which reflects a solid capital structure. However, the consistent negative net income impacts Return on Equity, limiting the potential returns to shareholders.
Cash Flow
50
Neutral
Seer has been facing negative Free Cash Flow, although there is a small improvement in the growth rate. The Operating Cash Flow to Net Income ratio reflects challenges in converting income into cash flow, a concern for ongoing operations. The cash flow metrics indicate a reliance on financing activities to support business operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue15.17M13.95M15.18M14.69M6.39M656.00K
Gross Profit6.11M6.83M7.03M6.74M3.19M656.00K
EBITDA-90.96M-93.92M-97.89M-93.29M-68.59M-31.17M
Net Income-85.87M-86.60M-86.28M-88.70M-68.63M-31.17M
Balance Sheet
Total Assets347.26M366.60M436.27M487.93M539.14M442.32M
Cash, Cash Equivalents and Short-Term Investments239.72M236.41M316.22M421.24M400.07M431.86M
Total Debt25.40M25.96M28.26M29.87M23.32M0.00
Total Liabilities36.26M39.03M39.37M40.94M36.22M10.71M
Stockholders Equity311.01M327.57M396.90M446.99M502.92M431.61M
Cash Flow
Free Cash Flow-50.55M-49.69M-66.37M-71.05M-53.27M-25.36M
Operating Cash Flow-47.07M-46.11M-59.06M-60.78M-46.35M-20.83M
Investing Cash Flow58.11M65.86M37.90M-122.72M-170.88M-34.56M
Financing Cash Flow-13.00M-11.49M452.00K3.89M116.63M371.49M

Seer Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.12
Price Trends
50DMA
2.03
Positive
100DMA
2.03
Positive
200DMA
2.09
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
51.02
Neutral
STOCH
37.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEER, the sentiment is Positive. The current price of 2.12 is above the 20-day moving average (MA) of 2.08, above the 50-day MA of 2.03, and above the 200-day MA of 2.09, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 51.02 is Neutral, neither overbought nor oversold. The STOCH value of 37.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SEER.

Seer Risk Analysis

Seer disclosed 67 risk factors in its most recent earnings report. Seer reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Seer Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
SLSLN
56
Neutral
$273.46M-99.23%-40.10%-16.60%
55
Neutral
$124.75M-24.73%-1.02%-8.59%
51
Neutral
$7.41B0.36-61.88%2.34%16.99%1.69%
51
Neutral
$268.77M123.38%10.49%47.31%
46
Neutral
$177.89M-32.97%
VOVOR
33
Underperform
$69.28M-125.43%2.98%
28
Underperform
$43.85M-41.96%72.12%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SEER
Seer
2.12
0.43
25.44%
ADCT
ADC Therapeutics
2.71
-0.97
-26.36%
KLRS
Kalaris Therapeutics
2.62
-14.17
-84.40%
SLN
Silence Therapeutics
5.79
-12.95
-69.10%
FDMT
4D Molecular Therapeutics
3.84
-17.50
-82.01%
VOR
Vor Biopharma
1.06
0.07
7.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025